Adelmidrol, in combination with hyaluronic acid, displays increased anti-inflammatory and analgesic effects against monosodium iodoacetate-induced osteoarthritis in rats

Rosanna Di Paola 1, Roberta Fusco 1, Daniela Impellizzeri 1, Marika Cordaro 1, Domenico Britti 2, Valeria Maria Morittu 2, Maurizio Evangelista 3 and Salvatore Cuzzocrea 1,4*

Abstract

Background: Osteoarthritis (OA) is a degenerative joint disease produced by a cascade of events that can ultimately lead to joint damage. The aim of this study was to evaluate the effect of adelmidrol, a synthetic palmitoylethanolamide analogue, combined with hyaluronic acid on pain severity and modulation of the inflammatory response in a rat model of monosodium iodoacetate (MIA)-induced osteoarthritis.

Methods: OA was induced by intra-articular injection of MIA in the knee joint. On day 21 post-MIA administration, the knee joint was analyzed. Rats subjected to OA were treated by intra-articular injection of adelmidrol in combination with sodium hyaluronate at different doses and time points after MIA induction. Limb nociception was assessed by the paw withdrawal latency and threshold measurement. Samples were examined macroscopically, histologically, and by immunohistochemistry.

Results: At day 21 post-MIA injection, the MIA + solvent and MIA + 1.0% sodium hyaluronate groups showed irregularities and fibrillation in the surface layer, a decrease in blood cells and multilayering in transition and radial zones, no pannus formation, and modified Mankin scores significantly higher than sham knees. The combination of hyaluronic acid and adelmidrol dose-dependently (adelmidrol 0.6% + 1.0% sodium hyaluronate and adelmidrol 2% + 1.0% sodium hyaluronate) reduced the histological alterations induced by MIA. Moreover, degeneration of articular cartilage, mast cell infiltration, and pro-inflammatory cytokine and chemokine plasma levels were significantly downregulated by treatment with a combination of hyaluronic acid and adelmidrol at the above doses.

Conclusions: Our results clearly demonstrate that the combination of hyaluronic acid and adelmidrol improves the signs of OA induced by MIA.

Keywords: Osteoarthritis, Adelmidrol, Sodium hyaluronate, Inflammation, Cartilage degeneration
**Background**

Osteoarthritis (OA) is one of the most common joint disabling disorders in adults [1]. It occurs when the protective cartilage on the ends of bones breaks down, causing pain, swelling, and problems in joint articulation [2]. OA is primarily characterized by degeneration of cartilage at the joints but also implicates other pathological changes, including synovial inflammation, osteophyte formation, and subchondral bone sclerosis, in all tissues of joints [3–5]. OA can affect any joint, but the disorder most frequently affects joints in the hands, knees, hips, and spine, where it induces stiffness and joint dysfunction. Current guidelines defined by The Osteoarthritis Research Society International state that OA treatment should be aimed at reducing pain and joint stiffness, maintaining and improving joint mobility, reducing physical disability, and improving patient quality of life by limiting progression of damage [6].

The monosodium iodoacetate (MIA) experimental model is commonly used as an animal model of arthritis pain associated with OA [7]. In particular, the MIA model has been widely used for the pharmacological evaluation of new drug therapy [8]. Nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids reduce the OA symptoms of joint pain and swelling [9]. However, evidence in clinics shows that pharmacological interventions, including acetaminophen, NSAIDS, topical agents, and intra-articular injections (e.g., steroids), and non-pharmacological interventions, such as joint replacement, are both sparse and controversial [10–12]. Glucocorticoids (GCs) have powerful immunosuppressive effects and are widely used in the management of chronic inflammatory diseases. Long-term therapy with GCs is often necessary to control the symptoms of osteoarthritis [13]. Important evidence shows that GCs are also used in association with hyaluronic acid (HA) and partially show an antinociceptive effect partially related to a viscoelastic lubricant effect [15, 16].

A major drawback in the use of HA relates to the ability of the intra-articular environment to depolymerize the polysaccharide with a speed directly proportional to the degree of intra-articular inflammation. The correct degradation of HA is therefore essential to maintain the integrity of tissues and, in particular, joint homeostasis. Moreover, an important question mark remains about therapeutic management of long-term pathologies, with steroids often linked to a series of unwanted side effects [17].

Adelmidrol is a semisynthetic derivative of azelaeic acid and analogue of the anti-inflammatory compound palmitoylethanolamide (PEA), an aliamide and member of the family of fatty acid amide signaling molecules with cannabimimetic properties. The anti-inflammatory and antinociceptive effects of the aliamides PEA and adelmidrol have been demonstrated in numerous preclinical studies, both in vitro and in vivo [18–20]. Their actions are thought to be due, at least in part, to their ability to down-modulate mast cell activation and mast cell mediator release in pathophysiological and pathological conditions [21].

The aim of the present study was to demonstrate that adelmidrol in association with HA is able to control depolymerization of exogenous HA, by bringing about a viscoelastic-type lubricating action and consequent modulation of inflammatory processes and pain in a rat model of MIA-induced OA.

**Methods**

**Animals**

Forty male Lewis rats (Sprague-Dawley, 200–230 g; Harlan, Nossan Milan, Italy) were maintained in a monitored environment and provided with standard rodent chow and water. The study was authorized by the University of Messina Review Board for the care of animals (Protocol number 8/U-apr16). Animal care was in conformity with Italian regulations for the protection of experimental animals (DM 116192) and with European Economic Community regulations (OJ of EC L 358/12/18/1986).

**Experimental protocol**

OA was induced by intra-articular injection of MIA in the knee joint [22]. On day 0, rats were anesthetized with 5.0% isoflurane (Baxter International). A volume of 25 μl sterile saline solution + 3 mg MIA was injected into the knee joint through the right infrapatellar ligament. The left knee received an equal volume of 0.9% sterile saline. MIA was prepared in sterile conditions and injected using a 50-μl Hamilton syringe with a 27-gauge needle that was inserted into the joint to about 2–3 mm. On day 21 post-MIA administration, knee joints were inspected in detail to determine histopathological changes. Cartilage was stained to verify the presence of OA or not.

**Experimental groups**

Rats were randomly divided into the following groups:

- **MIA + vehicle (solvent solution)**
  - Rats were subjected to induction of OA as described above, and received 25 μl of the solvent solution in the infrapatellar area of the right knee at days 3, 7, 14, and 21 (n = 10) by intra-articular injection.

- **MIA adelmidrol 0.6% + 1.0% sodium hyaluronate**
  - Rats were subjected to induction of OA as described above, and were treated by intra-articular injection of...
adelmidrol 0.6% + sodium hyaluronate 1.0% (sodium hyaluronate with high molecular weight, between 1.5 and 2.0 million daltons) at a dose of 150 μg/25 μl on days 3, 7, 14, and 21 after MIA induction (n = 10)

MIA adelmidrol 2% + sodium hyaluronate 1.0%
Rats were subjected to induction of OA as described above, and were treated by intra-articular injection of adelmidrol 2% + sodium hyaluronate 1.0% (sodium hyaluronate with high molecular weight, between 1.5 and 2.0 million daltons) at a dose of 150 μg/25 μl on days 3, 7, 14, and 21 after MIA induction (n = 10)

MIA + sodium hyaluronate 1.0%
Rats were subjected to induction of OA as described above, and were treated by intra-articular injection of sodium hyaluronate 1.0% (sodium hyaluronate with high molecular weight, between 1.5 and 2.0 million daltons) at a dose of 150 μg/25 μl on days 3, 7, 14, and 21 after MIA induction (n = 10)

Sham group
Rats were administered by intra-articular injection with 0.9% saline (25 μl) instead of MIA and were treated with either vehicle or different formulations on days 3, 7, 14, and 21 (n = 10)

Pain measurement
Mechanical sensitivity was evaluated using a dynamic plantar aesthesiometer (Ugo Basile, Comerio, Italy). The rats were placed on a metal mesh surface in a chamber in a room with a controlled temperature (22 °C) and they were allowed to adapt for 15 min before the testing began. The touch stimulator part was oriented under the animal. When the aesthesiometer was activated, a plastic monofilament touched the paw in the proximal metatarsal region. The filament exercised a gradually increasing force on the plantar, starting below the threshold of detection and increasing until the stimulus became painful and the rat removed its paw. The force required to produce a paw withdrawal reflex was recorded automatically and measured in grams. A maximum force of 50 g and a ramp speed of 20 s were used for all the aesthesiometry tests.

Analysis of motor function (Walking Track Analysis)
The rat was placed in a walking track with a dark end. White office paper of the appropriate size was placed on the bottom of the track. Hind limbs of the rat were dipped in ink, and the rat was allowed to walk along the track, leaving paw prints on the paper. The test was performed before induction on day 0 and at days 3, 7, 14, and 21 after induction [23]. The functionality index of the sciatic nerve (SFI), calculated by Walking Track Analysis, was evaluated at 60 min after the injection on days 3, 7, 14, and 21: values close to 0 indicate normal functioning, and values tending to −100 indicate an alteration of sciatic nerve functionality [24].

Micro-computed tomography analysis
In order to evaluate the bone mass and microarchitectural parameters, including the fraction of bone volume, the proximal and distal parts of the right tibiae were scanned using micro-computed tomography (Micro-CT; Skyscan, Belgium) The scan conditions were as follows: an aluminum filter of 0.5 mm, X-ray voltage of 50Kv, X-ray current of 200 mA, and an exposure time of 360 ms. After scanning, the cross-sectional slices were reconstructed and three-dimensional analyses were performed using CTAn SkyScan software.

Histological analysis
On day 21 after MIA administration, rats were sacrificed by anesthetic overdose and perfused with 4% paraformaldehyde solution. Tibiofemoral joints were collected and post-fixed in neutral buffered formalin (containing 4% formaldehyde), decalcified in EDTA, and processed as following described. After decalcification, the specimens were embedded in paraffin. Mid-coronal tissue sections (5 μm) were stained for evaluation; all histomorphometric analyses were performed by an observer blinded to the treatment groups. Sections were stained with hematoxylin and eosin and observed by light microscopy (Dialux 22 Leitz; Leica Microsystems SpA, Milan, Italy). Histopathological analysis of the cartilage was assessed by the modified score of Mankin [14] (score range 0 to 12, from normal to complete disorganization and hypocellularity).

Cartilage degeneration was assessed by staining with toluidine blue and analyzed using the following criteria described by Janusz et al. [25]: 1 = mild into the surface region; 2 = slightly extended in the upper center; 3 = moderate in the median area; 4 = extended area deep; and 5 = severe degeneration.

Mast cell staining
Identification of mast cells was performed as described previously [26]. Knee sections were cut at 5-μm thickness and stained with 0.25% toluidine blue, pH 2.5, for 45 min at room temperature. The sections were then dehydrated and mounted for viewing. Three non-sequential sections were chosen by a block at random from each paw for examination. All sections were evaluated at 200×, while some sections were photographed at 400× using a Nikon inverted microscope. The density of mast cells is expressed as the number of mast cells per unit area of bone tissue.
Measurement of cytokines, metalloproteinases, and nerve growth factor
The levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, nerve growth factor (NGF), and matrix metalloproteinase (MMP)-1, MMP-3, and MMP-9 were measured in serum. Assays were performed using commercial colorimetric enzyme-linked immunosorbent assay (ELISA) kits (TNF-α, IL-1β, and NGF: Thermo Fisher Scientific; MMP-1, MMP-3, and MMP-9: Cusabio).

Reagents
Unless otherwise stated, all compounds were obtained from Sigma-Aldrich Co. All other chemicals were of the highest commercial grade available. All stock solutions were prepared in non-pyrogenic saline (0.9% NaCl; Baxter Healthcare Ltd., Thetford, Norfolk, UK).

Data analysis
All values in the figures and text are expressed as mean ± standard error of the mean (SEM) of n observations. For in vivo studies, n represents the number of animals studied. In experiments involving histology, the figures shown are representative of at least three experiments performed on different days. The results were analyzed by one-way analysis of variance (ANOVA) followed by a Bonferroni post-hoc test for multiple comparisons. Non-parametric data were analyzed with the Fisher’s exact test. A P value less than 0.05 is considered significant.

Results
Effects of the HA and adelmidrol combination on OA pain production and motor function
Because pain is the predominant symptom of OA, the secondary tactile allostynia in MIA-induced OA rats was assessed. In the von Frey hair assessment test, the paw withdrawal latency (PWL) (Fig. 1b) and the paw withdrawal threshold (PWT) (Fig. 1a) were significantly prolonged in the inflamed hind paw of the rats given 0.6% adelmidrol + 1.0% sodium hyaluronate and 2% adelmidrol + 1.0% sodium hyaluronate compared with the MIA.
+ solvent group and the MIA + sodium hyaluronate 1.0% group, demonstrating the antinociceptive property of adelmidrol in a dose-dependent manner. The sham group showed no obvious change (Fig. 1a and b).

Moreover, we tested motor function using a walking track in order to demonstrate that the association of adelmidrol with sodium hyaluronate treatment may improve joint mobility and reduce physical disability. Analysis was performed on days 3, 7, 14, and 21 after induction of OA. As shown in Fig. 1c, the SFI in the sham group was normal throughout the experiment, with SFI approximating 0. In the MIA + vehicle and 1% sodium hyaluronate groups, SFI values on post-MIA administration on days 3, 7, 14, and 21 were significantly lower than those observed in the sham group. The combination of HA and adelmidrol (0.6% adelmidrol + 1.0% sodium hyaluronate and 2% adelmidrol + 1.0% sodium hyaluronate) dose-dependently improved motor function (Fig. 1c).

**Effects of the HA and adelmidrol combination on plasma levels of pro-inflammatory cytokines and NGF**

To test whether the association of adelmidrol with sodium hyaluronate treatment may modulate the secretion of pro-inflammatory cytokines, we analyzed plasma levels of TNF-α, IL-1β, and NGF. A significant increase in serum levels of TNF-α (Fig. 2a), IL-1β (Fig. 2b), and NGF (Fig. 2c) was observed in the MIA + vehicle and 1% sodium hyaluronate groups compared to sham animals. In contrast, the HA and adelmidrol combination (0.6% adelmidrol + 1.0% sodium hyaluronate and 2% adelmidrol + 1.0% sodium hyaluronate) dose-dependently reduced the increase in serum levels of TNF-α (Fig. 2a), IL-1β (Fig. 2b), and NGF (Fig. 2c) after administration of MIA.

**Effects of the HA and adelmidrol combination on mast cell infiltration**

An important source of cytokines, specifically TNF-α and IL-1β, is characterized by mast cell activation. Mast cell infiltration after OA induction was studied by staining knee joint tissues with toluidine blue. Degranulated mast cells were not seen in knee sections from the sham...
group (Fig. 3a; mast cell density in Fig. 3f). On the contrary, significant mast cell infiltration was observed in the MIA + solvent (Fig. 3b) and MIA + 1.0% sodium hyaluronate (Fig. 3c) groups in joint tissue near the subchondral bone taken 21 days after the induction of OA. The combination of HA and adelmidrol (0.6% adelmidrol + 1.0% sodium hyaluronate and 2% adelmidrol + 1.0% sodium hyaluronate) (Fig. 3d and e) dose-dependently reduced mast cell infiltration induced by administration of MIA.

Effects of the HA and adelmidrol combination on plasma levels of metalloproteinases
The progressive destruction of articular cartilage is caused by a number of matrix-degrading enzymes produced by the chondrocytes and synovium. Among the various biomarkers associated with OA, MMPs play a primary role in the downstream signaling pathways in OA and cartilage degradation. The MIA + vehicle and 1% sodium hyaluronate group showed a markedly higher expression of MMP-1 (Fig. 4a), MMP-3 (Fig. 4b), and MMP-9 (Fig. 4c). However, compared to the MIA group, the group treated with 0.6% adelmidrol + 1.0% sodium hyaluronate and, in particular, 2% adelmidrol + 1.0% sodium hyaluronate showed a decrease in MMP-1, MMP-3, and MMP-9 expression (Fig. 4a, b and c, respectively).

Effects of the HA and adelmidrol combination on OA articular cartilage degeneration
As indicated by toluidine blue O staining (Fig. 5), MIA intra-articular injection induced articular cartilage degeneration on the medial tibia platform in the MIA + solvent (Fig. 5b; cartilage degeneration scores in Fig. 5f) and MIA + 1.0% sodium hyaluronate (Fig. 5c) groups. Compared with knee joints in the MIA + solvent group, knees in the 0.6% adelmidrol + 1.0% sodium hyaluronate (Fig. 5d) group exhibited moderate cartilage degeneration; matrix and chondrocyte loss affected the middle to deep zone. The group with the higher treatment dose of 2% adelmidrol + 1.0% sodium hyaluronate showed no statistical improvement in cartilage degeneration (Fig. 5e). Sham knee joints (Fig. 5a) showed no obvious changes.

Effects of the HA and adelmidrol combination on OA subchondral bone
In order to demonstrate the crucial role of subchondral bone in the pathogenesis and progression of OA, knee sections 21 days after MIA induction were examined for the number of osteoclasts and bone volume. In the MIA + solvent (Fig. 6b; cell number per joint in Fig. 6f) and MIA + 1.0% sodium hyaluronate (Fig. 6c) groups, the number of osteoclasts was increased after MIA injection. Compared with knee joints in the MIA + solvent group, knees in the 0.6% adelmidrol + 1.0% sodium hyaluronate (Fig. 6d) group exhibited a moderately increased number of osteoclasts. The higher treatment dose of 2% adelmidrol + 1.0% sodium hyaluronate showed no statistical improvement in cell numbers (Fig. 6e). There is no variation in cell numbers in Sham knee joints (Fig. 6a). Moreover, to quantify the structural changes in the subchondral bone in MIA-induced OA, each rat was scanned for bone volume density (mm$^3)$ (Fig. 6g). Compared with the MIA + solvent and MIA + 1.0% sodium hyaluronate groups, 0.6% adelmidrol + 1.0% sodium hyaluronate and the higher treatment dose of 2% adelmidrol + 1.0% sodium hyaluronate showed a marked increase in bone volume (Fig. 6g). Thus, treatment with 0.6% adelmidrol + 1.0% sodium hyaluronate and the higher treatment dose of 2% adelmidrol + 1.0% sodium hyaluronate showed significant and dose-dependent effects on MIA-induced deterioration of the subchondral bone.
Effects of the HA and adelmidrol combination on OA histopathology

In order to demonstrate that adelmidrol promotes the beneficial and lubricant action of HA, knee sections were stained with hematoxylin and eosin 21 days after intra-articular injection of MIA. Histological examination by light microscopy showed irregularities and fibrillation in the surface layer, a decrease in blood cells and multilayering in transition and radial zones, no pannus formation, and modified Mankin scores (Fig. 7f) in the MIA + solvent and MIA + sodium hyaluronate 1.0% knees groups (Fig. 7b and c, respectively; see Mankin scores in Fig. 7f) compared to sham knees. The combination of HA and adelmidrol (0.6% adelmidrol + 1.0% sodium hyaluronate (Fig. 7d) and 2% adelmidrol + 1.0% sodium hyaluronate (Fig. 7e)) reduced, in a dose-dependent manner, the histological alterations induced by administration of MIA.

Discussion

OA is a complex disease with inflammatory mediators released by cartilage, bone, and synovium [27]. Numerous inflammatory mediators contribute to both degradative and nociceptive pathways associated with the progression of pathology. Inflammatory stimuli initiate a cascade of events, including the release of cytokines by chondrocytes, leading to complex biochemical and mechanical interplay with other biological mediators to induce OA and promote pain [27, 28].

Although the role of cytokines in the pathogenesis of OA is not yet clear, several in vitro studies support an elevated catabolic role for cytokines in the OA joint. IL-1β and TNF-α signaling, culminating in the activation of nuclear factor-κB and activator protein 1 transcription factors, can induce autocrine production of IL-1β and TNF-α as well as expression of other critical inflammatory and chondrolytic mediators, including MMP1, MMP9, MMP13, nitric oxide, prostaglandin E2, IL-6, and pain [29].

Moreover it has been demonstrated that IL-1β induces an increase in levels of NGF [30]. NGF is a key factor in hyperalgesia associated with inflammation, whose protein is detected in OA synovial fluid [31]. NGF synthesis
is highly correlated with the degree of cartilage degradation in human OA [32]. Clinical trials have demonstrated that acting against NGF leads to a dramatic reduction in OA pain [33]. In this study, we confirmed an increase in cytokine production and showed that treatment with HA in combination with adelmidrol in increasing doses significantly reduced pro-inflammatory cytokine levels and NGF expression.

The literature indicates that an important source of cytokines, specifically TNF-α and IL-1β, is also characterized by mast cell activation. There is a well-established correlation between mast cell numbers and total inflammatory infiltrate. Mast cells are potent regulators of vascular permeability and have a crucial role in the recruitment of leukocytes to OA joints. Degranulated mast cells have been found in OA synovium [34], and Buckley and Walls [35] reported a selective expansion and higher ratio of mast cell tryptase phenotype in OA synovium, a phenotype consistent with degranulation.

The present study confirms an increased infiltration of mast cells in the knee joint after MIA administration, and their consequent reduction after treatment with HA in combination with adelmidrol in increasing doses. Mast cells in the joint capsule become hyper-reactive due to joint inflammation, a process markedly influenced by the degradation of HA caused by the in situ release of β-hexosaminidase [36, 37]. In fact, OA animals and those treated only with HA displayed a significant degeneration of articular cartilage. Significant restoration of cartilage was achieved after treatment with increasing doses of HA and adelmidrol in combination.

Along with progressive loss of articular cartilage, OA is characterized by increased subchondral bone sclerosis with thickening of the cortical plate, extensive remodeling of the trabeculae, formation of new bone at the joint margins (osteophytes), and the development of subchondral bone cysts. Changes to subchondral bone are due to increased osteoclastic bone resorption and changes in bone density.
Our study demonstrated that adelmidrol and hyaluronic acid treatment showed significant and dose-dependent effects on MIA-induced deterioration of the subchondral bone, reducing osteoclastic bone resorption.

Strong evidence associates subchondral bone alterations with cartilage damage and pain severity in OA [38]. In this study, motor functionality was evaluated by Walking Track Analysis. An SFI value of approximately zero indicates normal locomotor function, while a value close to -100 indicates significant impairment of locomotor function. As expected, intra-articular injection of MIA resulted in a significant increase in joint discomfort. Importantly, the combination of HA and adelmidrol, in a dose-dependent fashion, completely restored locomotor functionality.
Conclusions

Our results clearly demonstrated that a combination of HA and adelmidrol dose-dependently produced a significant reduction in: 1) pain severity; 2) OA histopathology; 3) articular cartilage degeneration; 4) mast cell infiltration; 5) pro-inflammatory cytokines, MMPs, and NGF production; and 6) the degree of motor function.

The association of HA with adelmidrol is accompanied by a reduced depolymerization of HA, which would otherwise be promoted by intra-articular inflammation.

Moreover application of infiltrative adelmidrol produces a significant increase in endogenous PEA levels [39], which are found to be significantly reduced in joint inflammation [40]. Several of our works demonstrated the beneficial effects of PEA alone and in combination in different models of inflammation and pain [41, 42], such as in a mouse model of collagen-induced arthritis (CIA) [19]. Thus, local analgesic and anti-inflammatory effects observed with adelmidrol treatment could be useful in the treatment of inflammatory diseases associated with pain.

Abbreviations

GC: Glucocorticoid; HA: Hyaluronic acid; IL: Interleukin; MIA: Monosodium iodoacetate; MMP: Matrix metalloproteinase; NGF: Nerve growth factor; NSAID: Nonsteroidal anti-inflammatory drug; OA: Osteoarthritis; PEA: Palmitoylethanolamide; PWL: Paw withdrawal latency; PWT: Paw withdrawal threshold; SFI: Sciatic nerve functionality index; TNF: Tumor necrosis factor

Acknowledgements

The authors would like to thank Mrs. Medici Maria Antonietta for excellent technical assistance during this study, Mr. Francesco Soraci for secretarial and administrative assistance, and Miss. Malvagni Valentina for editorial assistance with the manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

The authors declare that all data supporting the findings of this study are available within the article. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Authors’ contributions
RDP designed the study and drafted the manuscript. RF carried out the immunoassays and revised the manuscript. DI participated in the design of the study. MC helped to revise the manuscript. DB conceived of the study. VMM performed the statistical analysis. ME helped to draft the manuscript. SC drafted and revised the manuscript. All authors read and approved the final manuscript.

Competing interests
SC is co-inventor on patent WO2013121449 A8 (Epitech Group Srl) which deals with methods and compositions for the modulation of amidases capable of hydrolysing N-acyl ethanolamines employable in the treatment of inflammatory diseases. This invention is wholly unrelated to the present study. Moreover, SC is also, with Epitech Group, a co-inventor on the following patents, EP 2 821 083, M2014 A001495, and 10201500067344, that are unrelated to the study. The remaining authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval
Animal care was in conformity with Italian regulations for the protection of experimental animals (DM 116192) and with European Economic Community Ethics approval. Not applicable.

The remaining authors declare that they have no competing interests.

Received: 29 August 2016 Accepted: 21 November 2016
Published online: 12 December 2016

References
1. Duncan R, Peat G, Thomas E, Hay EM, Croft P. Incidence, progression and sequence of development of radiographic knee osteoarthritis in a symptomatic population. Ann Rheum Dis. 2011;70(1):1944–8.
2. Longo UD, Loppini M, Fumo C, Rizzello G, Khan WS, Maffulli N, Denaro V. Osteoarthritis new insights in animal models. Open Orthop. 2012;6538–63.
3. Bian Q, Wang YJ, Liu SF, Li YP. Osteoarthritis: genetic factors, animal models, mechanisms, and therapies. Front Biosci (Elite Ed). 2012;474–100.
4. Loeser RF, Goldberg SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–707.
5. Little CB, Hunter DJ. Post-traumatic osteoarthritis: from mouse models to clinical trials. Nat Rev Rheum. 2013;9(8):485–97.
6. Zhang W, Moskowtiz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16(2):137–62.
7. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K. Detection of aggrecanase- and MMP-generated catalytic neoepitopes in the rat iodoacetate model of cartilage degeneration. Osteoarthr Cartil. 2004;12(9):720–8.
8. Ahmad A, Cruip R, Impellizzeri D, Campo N, Marino A, Esposito E, Cuzzocrea S. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain Behav Immun. 2012;26(8):1310–21.
9. Farnworth ER. Mechanisms of chronic pain in osteoarthritis. Curr Rheumatol Rep. 2012;14(6):549–56.
10. Read SJ, Dray A. Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. Expert Opin Investig Drugs. 2008;17(5):619–40.
11. Attur MG, Patel IR, Abramson SB, Amin AR. Autocrine production of IL-1 beta by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc Assoc Am Physicians. 1998;110(1):65–72.
12. Manli L, Aloe L. Role of IL-1 beta and TNF-alpha in the regulation of NGF in experimental arthritis. Eur Biophys J. 2000;29(4):253–5.
13. Riis RG, Henriksen M, Kliokker L, Bartholdy C, Ellekaard K, Bandak E, Hansen BB, Bliddal H, Boesen M. The effects of intra-articular glucocorticoids and exercise on pain and synovitis assessed on static and dynamic magnetic resonance imaging in knee osteoarthritis: exploratory outcomes from a randomized controlled trial. Osteoarthr Cartil. 2016.
14. Calazyński K, Trybik G, Smolek T, Masiuk M, Mysliwiec L, Spornik-Tutak K. Effect of methylprednisolone, hyaluronic acid and piroglutamate on histological remodeling of temporomandibular joint cartilage in rabbits affected by drug-induced osteoarthritis. Postepy Hig Med Dosw. 2016;70:74–9.
15. Morgan TK, Jensen E, Lim J, Riggs R. Image-guided hyaluronic acid injection and knee bracing significantly improve clinical outcomes for high-grade osteoarthritis. Sports Med Open. 2015;1(1):31.
16. Galluccio F, Baskova T, Cenicic MM. Short-term effect of the combination of hyaluronic acid, chondroitin sulfate, and keratin matrix on early symptomatic knee osteoarthritis. Eur J Rheumatol. 2015;2(3):106–8.
17. Richette P. Pharmacological therapies for osteoarthritis. Therapie. 2011;66(5):383–90.
18. De Filippis D, D’Amico A, Cinelli MP, Esposito G, Di Marzo V, Iuvone T, Adelmödl, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats. J Cell Mol Med. 2009;13(6):1086–95.
19. Impellizzeri D, Esposito E, Di Paola R, Ahmad A, Campolo M, Pelli A, Moritru VM, Britti D, Cuzzocrea S. Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice. Arthritis Res Ther. 2013;15(6):R192.
20. Di Paola R, Impellizzeri D, Torre A, Mazzon E, Cappellani A, Faggio C, Esposito E, Trischitta F, Cuzzocrea S. Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice. J Leukoc Biol. 2012;91(6):911–20.
21. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabinimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J. 2007;173(1):21–30.
22. Vonsy L, Ghandeheri J, Dickerson AH. Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. Eur J Pain. 2009;13(8):786–93.
23. Wong KH, Naidu M, David P, Abdullah MA, Abdulrah N, Kuppusamy UR, Sabarathnam V. Peripheral nerve regeneration following crush injury to rat peroneal nerve by aqueous extract of medicinal mushroom Hericium erinaceus (Bull.: Fr) Pers. (Aphylrophoromyceae). Evid Based Complement Alternat Med. 2011;2011:857025.
24. Sankicioglu L, Demirel BM, Utuk A. Walking track analysis: an assessment method for functional recovery after sciatic nerve injury in the rat. Folia Morphol (Warsz). 2009;68(1–2):1–7.
25. Janusz MJ, Little CB, King LE, Hookfin EB, Brown KK, Heitmeyer SA, Caterson ID, Boileau AR, Taiwo YC. Detection of aggrecanase- and MMP-generated catalytic neoepitopes in the rat iodoacetate model of cartilage degeneration. Osteoarthr Cartil. 2004;12(9):720–8.
26. Ahmad A, Crupi R, Impellizzeri D, Campo N, Marino A, Esposito E, Cuzzocrea S. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain Behav Immun. 2012;26(8):1310–21.
27. Schibille HG. Mechanisms of chronic pain in osteoarthritis. Curr Rheumatol Rep. 2012;14(6):549–56.
28. Read SJ, Dray A. Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. Expert Opin Investig Drugs. 2008;17(5):619–40.
29. Attur MG, Patel IR, Patel RN, Abramson SB, Amin AR. Autocrine production of IL-1 beta by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc Assoc Am Physicians. 1998;110(1):65–72.
30. Manli L, Aloe L. Role of IL-1 beta and TNF-alpha in the regulation of NGF in experimentally induced arthritis in mice. Rheumatol Int. 1998;18(3):97–102.
31. Aloe L, Tuveri MA, Caracci U, Levi-Montalcini R. Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum. 1992;35(3): 351–5.
32. Iannone F, De Bari C, Dell’Accio F, Covelli M, Patella V, Lo Bianco G, Lapadula G. Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes. Rheumatology. 2002;41(12):1413–8.
33. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT, Tatezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363(16):1521–31.
34. Dean G, Hoyland JA, Denton J, Donn RP, Freemont AJ. Mast cells in the synovium and synovial fluid in osteoarthritis. Br J Rheumatol. 1993;32(8):671–5.
35. Buckley M, Walls AF. Identification of mast cells and mast cell subpopulations. Methods Mol Med. 2008;138:285–97.
36. Masuko K, Murata M, Yudoh K, Kato T, Nakamura H. Anti-inflammatory effects of hyaluronan in arthritis therapy: not just for viscosity. Int J Gen Med. 2009;2:77–81.
37. Guo N, Baglole CJ, O’Loughlin CW, Feldon SE, Phipps RP. Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease. J Biol Chem. 2010;285(21):15794–804.
38. Li G, Yin J, Gao J, Cheng TS, Pavlos NJ, Zhang C, Zheng MH. Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes. Arthritis Res Ther. 2013;15(6):223.
39. Petrosino S, Puigdemont A, Della Valle MF, Fusco M, Verde R, Allara M, Aveta T, Orlando P, Di Marzo V. Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis. Vet J. 2016;207:85–91.
40. Richardson D, Ortori CA, Chapman V, Kendall DA, Barrett DA. Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal Biochem. 2007;360(2):216–26.
41. Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, Cuzzocrea S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation. 2014;11:136.